Security key
59045L106
Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN)
CUSIP: 59045L106
Q3 2022 13F Holders as of 30 Sep 2022
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 92,449,667
- Total 13F value
- $624,973,128
- Share change
- +4,416,480
- SEC-reported price per share
- $6.76
- Number of holders
- 147
- Value change
- +$39,050,654
- Number of buys
- 100
- Number of sells
- 38
- Shares outstanding
- 4,992,318
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2022
Institutions
147
Top holders
10
MRSN full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Mersana Therapeutics, Inc. SEC filings
Mersana Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 59045L106
Recent filing periods:
Ownership snapshot
Top reported holders of MRSN - Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Jun 2022
13F
Lead comparable stake: 181%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 181%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
181%
BlackRock Finance, Inc.
178%
Bain Capital Life Sciences Invest...
174%
Avoro Capital Advisors LLC
151%
VANGUARD GROUP INC
95%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
181%
|
$41,633,000
9,011,437 shares
|
— | 30 Jun 2022 |
| BlackRock Finance, Inc. |
13F
Company
|
178%
|
$41,030,000
8,881,019 shares
|
— | 30 Jun 2022 |
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
174%
|
$40,026,000
8,663,673 shares
|
— | 30 Jun 2022 |
| Avoro Capital Advisors LLC |
13F
Company
|
151%
|
$34,881,000
7,550,000 shares
|
— | 30 Jun 2022 |
| VANGUARD GROUP INC |
13F
Company
|
95%
|
$21,871,000
4,733,731 shares
|
— | 30 Jun 2022 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
88%
|
$20,248,000
4,382,701 shares
|
— | 30 Jun 2022 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2022
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
147
Shares
92,449,667
Rows available
147
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2022 vs Q4 2025 Across Filers
Q4 2025 holders
3
Q3 2022 holders
147
Holder diff
144
| Investor | Q4 2025 Shares | Q3 2022 Shares | Share Diff | Share Chg % | Q4 2025 value | Q3 2022 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend